However, prolonged injections of anti-PD-1 mAb after tumour clearance in this study appeared to cause CAR T cell dysfunction, with mice relapsing or failing to prevent tumour outgrowth after tumour rechallenge (176). Here, PDCD1 is linked to neoplasm.